Register Log-in Investor Type


AAV is an acronym for Adeno-associated virus. They are the leading platform for gene delivery for the treatment of a variety of human diseases. The first AAV-based gene therapy drug, Glybera, was approved by the European Medicines Agency in 2012. This article has much more information.

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…